Divi's Laboratories
Divi's Laboratories Limited is an Indian pharmaceutical manufacturer specializing in active pharmaceutical ingredients (APIs) and intermediate compounds. The company operates through two core business areas: Generic APIs and Custom Synthesis for innovator biopharmaceutical companies. Its product lines encompass active ingredients for anti-inflammatory treatments, nutraceutical carotenoids, and complex chemical intermediates. Revenue is generated through the export and direct sale of high-volume APIs and proprietary contract synthesis services to global pharmaceutical players. Divi's Laboratories holds a leading global market position as a top producer of active ingredients such as Naproxen and Dextromethorphan. The company is headquartered in Hyderabad, India, and its shares are listed on the National Stock Exchange of India and BSE Limited.
21 of the funds FundTelligence covers report a position in Divi's Laboratories.
- Legal name
- Divi's Laboratories Ltd
- Sector
- Health Care
- Country
- India
- Funds holding it
- 21
Funds holding Divi's Laboratories
- Schroder Indian Opportunities — Schroders · 2.55 % (largest positions only, October 2026)
- Nordea India — Nordea Funds · 2.15 % (full portfolio disclosed, September 2026)
- Franklin India Fund — Franklin Templeton · 2.14 % (full portfolio disclosed, September 2026)
- T. Rowe Price Asian ex Jp Equity — T. Rowe Price · 1.19 % (full portfolio disclosed, September 2026)
- T. Rowe Price Emerging Markets Equity Fund — T. Rowe Price · 0.69 % (full portfolio disclosed, September 2026)
- Storebrand Emerging Markets Plus — Storebrand · 0.4 % (full portfolio disclosed, October 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.18 % (full portfolio disclosed, September 2026)
- Danske Invest Global Emerging Markets Index Restricted — Danske Invest · 0.16 % (full portfolio disclosed, July 2026)
Showing the 8 largest of 21 funds holding it.